Lynparza (olaparib) / Merck (MSD), AstraZeneca - LARVOL DELTA

Adjuvant olaparib in germline BRCA carriers: new certainties and remaining open questions from the updated OlympiA results. (PubMed, Ann Oncol) - No abstract available

Journal • Breast Cancer • Oncology • Solid Tumor • BRCA

OPTIMUM: A randomized phase 2 study of maintenance olaparib (Ola) with or without durvalumab (Durva) in DDR gene-mutated advanced biliary tract cancer (aBTC) (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Metastases • P2 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Combination Immunotherapy in Pancreatic Cancer: Current Clinical Evidence and Mechanistic Rationale for Overcoming a "Cold" Tumor. (PubMed, Cancers (Basel)) - "POLAR did not meet its co-primary activity criteria; preliminary SWOG S2001 results did not demonstrate benefits from adding pembrolizumab to olaparib. Human immune changes, immunogenicity and target engagement should not be equated with clinical efficacy. Future trials should test defined component contributions, appropriate pharmacodynamic hypotheses and patient-reported outcomes, with sampling adapted to disease setting and feasibility."

IO biomarker • Journal • Review • Microsatellite Instability • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • MSI

Proteasome-dependent degradation of DAPK1 by wogonoside blocks PARthanatos and protects against ischemic stroke. (PubMed, Neuropharmacology) - "WS-induced degradation intercepted the JNK-mitochondrial depolarization-AIF nuclear translocation cascade while leaving PARP1 catalytic activity, PAR polymer formation, and γH2AX resolution fully intact-in stark contrast to the clinical PARP1 inhibitor olaparib...Single-nucleus RNA sequencing revealed Dapk1 enrichment in activated microglia and co-variation with neuronal MAPK pro-death signaling, suggesting a dual-compartment mechanism. These findings define proteasome-dependent DAPK1 degradation as a mechanistically distinct antioxidant strategy for acute ischemic stroke."

Journal • Cardiovascular • Ischemic stroke • DAPK1

Focal adhesion kinase inhibitor defactinib enhances olaparib-induced suppression of BRCA-proficient breast cancer cell proliferation. (PubMed, Oncol Lett) - "To elucidate the molecular mechanisms underlying the enhanced induction of apoptosis, a Western blot analysis of apoptosis-related proteins indicated the contribution of the downregulated expression of X-linked inhibitor of apoptosis protein. This indicates the efficiency of the combination treatment of the PARP inhibitor olaparib and the FAK inhibitor defactinib for breast cancer cells, which may be useful for BRCA-proficient breast cancer or carcinomas that acquire resistance to PARP inhibitors."

Journal • Breast Cancer • Oncology • Solid Tumor • BRCA • BRCA1 • BRCA2 • XIAP

OlympiaN: Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer (clinicaltrials.gov) - P2 | N=50 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Monotherapy • Trial completion • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • BRCA • BRCA1 • BRCA2 • ER • HER-2

Randomized Prospective Comparison Between Neoadjuvant Mitomycin C Plus Cisplatin and Paclitaxel Plus Carboplatin in Patients With BRCA1-Associated Ovarian Cancer. (PubMed, Int J Cancer) - P=N/A | "Maintenance olaparib, complete cytoreduction, resolution of carcinomatosis, and TP53 mutation type (loss-of-function (LOF) versus non-LOF) were associated with improved disease-free interval (DFI). In conclusion, MP showed no significant efficacy advantage over TCbP but produced a rapid and profound reduction of tumor burden, thus warranting further evaluation. Trial Registration: ClinicalTrials.gov (identifier: NCT04747717)."

Journal • Hematological Disorders • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Solid Tumor • Thrombocytopenia • BRCA1 • BRCA2 • TP53

WIRE - Novel Treatments in Renal Cell Cancer (clinicaltrials.gov) - P2 | N=134 | Recruiting | Sponsor: CCTU- Cancer Theme | N=60 ➔ 134 | Trial completion date: Nov 2025 ➔ Dec 2027 | Trial primary completion date: Nov 2025 ➔ Dec 2027

Enrollment change • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • IL2 • TIGIT

Concurrent EGFR exon 19 deletion-insertion and germline BRCA1 alteration in KRAS-wild-type pancreatic ductal adenocarcinoma: A case report and review of therapeutic implications. (PubMed, Oncol Lett) - "The patient developed clinically suspected postoperative recurrence and subsequently achieved durable disease control following individualized exploratory treatment with aumolertinib and olaparib. The present case provides a clinically documented observation of individualized targeted therapy in a rare KRAS wild-type PDAC molecular context and may help inform future hypothesis-driven investigations in selected molecularly defined patients. However, further studies are required to clarify the functional relevance of these molecular alterations and the clinical value of this treatment approach in selected patients with molecularly unique PDAC."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • BRCA1 • BRCA2 • EGFR • HER-2 • KRAS • TP53

Clinical Evaluation of Olaparib Maintenance Therapy in BRCA-Mutated Pancreatic Ductal Adenocarcinoma: Insights from Phase III Trials, Real-World Evidence, and the SEER Database (ESMO 2026) - No abstract available

Clinical • HEOR • P3 data • Real-world • Real-world evidence • Oncology • Pancreatic Ductal Adenocarcinoma • BRCA

Real-world safety and outcomes of first-line (1L) olaparib plus abiraterone (OLA+ABI) in metastatic castration-resistant prostate cancer (mCRPC), and a comparison with docetaxel (DOC) (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Baseline genomic landscape and disease burden correlates in bone-metastatic castration resistant prostate cancer: Results from the phase 2 COMRADE trial of radium-223 ± olaparib (ESMO 2026) - No abstract available

Metastases • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

PROWESs STUDY: First interim analysis of olaparib use in metastatic Castration-Resistant Prostate Cancer (mCRPC) in routine practice (ESMO 2026) - No abstract available

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Safety of Spine Radiotherapy Delivered within 6 Months of Lu-177 PSMA Radioligand Therapy in Metastatic Prostate Cancer (ASTRO 2026) - "Median prior systemic therapy lines was 3 (IQR 2-4) and included taxanes (100%), olaparib (24%), platinum (17%), and radium-223 (15%); patients who received endocrine therapy (both ADT and ARPI) and 3 other lines of systemic therapy were defined as heavily pretreated (35%). In this cohort treated with spine RT and Lu-177 PSMA RLT, severe toxicity was primarily hematologic with no high-grade spine RT-site complications. G3+ AE were associated with cumulative RLT exposure rather than RT sequencing or extent of spine treatment, supporting the safety of integrating these modalities. Longer follow-up is needed to fully characterize the safety conclusion."

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Clinical characteristics, treatment patterns and outcomes of treatment with Olaparib in BRCA-mutated HER2-negative breast cancer: real-world data from Kazakhstan (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • BRCA • HER-2

Persistent Luminescent GOLC-Based Nanotheranostics for Enhanced Synergistic Chemo-Radiotherapy of Oral Squamous Cell Carcinoma (ASTRO 2026) - "The PARP inhibitor olaparib was loaded onto GOLCs and coated with cationic protamine (GOLC@OLA-PRM)... This integration achieves precise spatial correlation between nanoparticle localization, background-free imaging, and targeted drug delivery. By combining optical tracking with image-guided chemo-radiotherapy within a single system, this study establishes a versatile NIR luminescent framework, providing a materials-centric foundation for OSCC management and oncological nanomedicine. Keywords: Near-infrared (NIR) luminescent nanoparticles, oral squamous cell carcinoma (OSCC), radiotherapy"

Oncology • Oral Cancer • Squamous Cell Carcinoma

Olaparib in molecularly selected advanced/metastatic solid tumors: final results from the randomized phase II MOST-Plus clinical trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Solid Tumor

Mechanistic Study of PARP Inhibitor Olaparib Combined with Low-Dose Radiotherapy and PD-1 Blockade in Reversing Tumor Immune Desertification and Therapeutic Resistance in Ovarian Cancer (ASTRO 2026) - "The combination of the PARP inhibitor olaparib with low-dose radiotherapy and PD-1 blockade markedly remodels the ovarian cancer tumor immune microenvironment through multifaceted immunoregulatory mechanisms, effectively reversing immune desertification and overcoming therapeutic resistance. LDRT serves as a critical immune reprogramming component in this combinatorial strategy, providing important experimental evidence for the integrated application of radiotherapy, targeted therapy, and immunotherapy."

IO biomarker • Oncology • Ovarian Cancer • Solid Tumor • CD8

Longitudinal ctDNA tumor fraction (TF) as a prognostic biomarker in bone-dominant metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 ± olaparib: Results from the phase 2 COMRADE trial. (ESMO 2026) - No abstract available

Biomarker • Circulating tumor DNA • Metastases • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

AGO OVAR 27, a non-randomised phase II window-of-opportunity (WoO) trial of olaparib (Ola) alone (cohort A) or in combination with durvalumab (cohort B) prior to primary debulking surgery (PDS) in high-grade ovarian cancer (OC): primary results of cohort A. (ESMO 2026) - No abstract available

Clinical • Combination therapy • P2 data • Surgery • Oncology • Ovarian Cancer • Solid Tumor

Pembrolizumab plus bevacizumab with platinum-based chemotherapy followed by pembrolizumab, bevacizumab and olaparib maintenance in platinum-sensitive recurrent ovarian cancer: phase II SaINT-ov02 (ESMO 2026) - No abstract available

Clinical • P2 data • Platinum sensitive • Oncology • Ovarian Cancer • Solid Tumor

Pembrolizumab (P) plus Olaparib (O) in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC): The Phase II PEMBROLA, GEMCAD-2102 TRIAL (ESMO 2026) - No abstract available

Metastases • P2 data • Colorectal Cancer • Oncology • Solid Tumor • HRD

Health-related quality of life during and after intensified alkylating chemotherapy or olaparib for stage III, HRD breast cancer patients (ESMO 2026) - No abstract available

Clinical • HEOR • Breast Cancer • Oncology • Solid Tumor

Quantitative PARP1 H-score as a predictive biomarker for trabectedin plus olaparib combination in advanced soft tissue sarcoma: exploratory analysis of the TOMAS2 study (ESMO 2026) - No abstract available

Biomarker • Metastases • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • PARP1

Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): interim overall survival (OS) and safety from the randomised Phase 3 DUO-E/GOG-3041/ENGOT-EN10 study (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Metastases • P3 data • P3 data: top line • Endometrial Cancer • Gynecologic Cancers • Oncology